CPE’s ESMO 2024 advisory board report examines barriers to shared decision-making in breast cancer care, with recommendations for clinicians and patient organisations. Read More
CPE’s myC patient survey assessed genomic testing awareness in early breast cancer across 5 EU countries. Findings shaped the myC White Paper and policy recommendations. Read More
See the myC survey results: 4 in 5 eligible breast cancer patients weren’t told about genomic testing. View infographics for 5 European countries. Read More
CPE’s ESMO 2023 poster reveals only 1 in 5 eligible breast cancer patients were told about genomic testing. See the European survey data. Read More
CPE’s myC White Paper reveals 78% of eligible breast cancer patients were never told about genomic testing. Read the Call to Action for Europe. Read More